SLC5A2 and diabetic kidney disease: The use of SGLT-2 inhibitors was linked with a 29% reduction in risk of cardiovascular events (HR 0.71, 95% CI 0.63–0.80) [78] in a meta-analysis of individuals with DKD stage 3–4.